Cyclerion Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters02-28

Cyclerion <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc <cycn.oq> expected to post a loss of 38 cents a share - Earnings Preview </cycn.oq>

Cyclerion Therapeutics Inc CYCN.OQ CYCN.O is expected to report resultson March 2 (estimated) for the period ending December 31 2025
The Cambridge Massachusetts-based company is expected to report revenue of $100 thousand, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Cyclerion Therapeutics Inc is for a loss of 38 cents per share.
Wall Street's median 12-month price target for Cyclerion Therapeutics Inc is $8.00, about 510.7% above its last closing price of $1.31

This summary was machine generated February 27 at 21:25 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614867842?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-28 05:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614867842","market":"nz","top_or_hot":-1,"title":"Cyclerion Therapeutics Inc  expected to post a loss of 38 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cyclerion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <cycn.oq> expected to post a loss of 38 cents a share - Earnings Preview </cycn.oq></title></head><body><ul><li><p>Cyclerion Therapeutics Inc <span>CYCN.OQ</span> <span>CYCN.O</span> is expected to  report resultson March 2 (estimated) for the period ending December 31 2025</p></li><li><p>The Cambridge Massachusetts-based  company is expected to report revenue of $100 thousand, according to the estimate from one analyst, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Cyclerion Therapeutics Inc is for a loss of 38 cents per share. </p></li><li></li><li><p></p></li><li><p>Wall Street's median 12-month price target for Cyclerion Therapeutics Inc is $8.00, about 510.7% above its last closing price of $1.31</p></li></ul><p>This summary was machine generated February 27 at 21:25 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cyclerion Therapeutics Inc  expected to post a loss of 38 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCyclerion Therapeutics Inc  expected to post a loss of 38 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-28 05:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Cyclerion <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <cycn.oq> expected to post a loss of 38 cents a share - Earnings Preview </cycn.oq></title></head><body><ul><li><p>Cyclerion Therapeutics Inc <span>CYCN.OQ</span> <span>CYCN.O</span> is expected to  report resultson March 2 (estimated) for the period ending December 31 2025</p></li><li><p>The Cambridge Massachusetts-based  company is expected to report revenue of $100 thousand, according to the estimate from one analyst, based on LSEG data.</p></li><li><p>LSEG's mean analyst estimate for Cyclerion Therapeutics Inc is for a loss of 38 cents per share. </p></li><li></li><li><p></p></li><li><p>Wall Street's median 12-month price target for Cyclerion Therapeutics Inc is $8.00, about 510.7% above its last closing price of $1.31</p></li></ul><p>This summary was machine generated February 27 at 21:25 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CYCN","symbol_name":"Cyclerion Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL8N3ZN2QZ:1","article_id":"2614867842","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614867842","pubTimestamp":1772227504,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cyclerion Therapeutics Inc  expected to post a loss of38cents a share - Earnings Preview Cyclerion Therapeutics Inc CYCN.OQ CYCN.O is expected to  report resultson March 2 (estimated) for the period e","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CYCN":"Cyclerion Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Cyclerion Therapeutics Inc预计每股亏损38美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYCN":0.9},"content_text":"Cyclerion Therapeutics Inc  expected to post a loss of 38 cents a share - Earnings Preview Cyclerion Therapeutics Inc CYCN.OQ CYCN.O is expected to  report resultson March 2 (estimated) for the period ending December 31 2025The Cambridge Massachusetts-based  company is expected to report revenue of $100 thousand, according to the estimate from one analyst, based on LSEG data.LSEG's mean analyst estimate for Cyclerion Therapeutics Inc is for a loss of 38 cents per share. Wall Street's median 12-month price target for Cyclerion Therapeutics Inc is $8.00, about 510.7% above its last closing price of $1.31This summary was machine generated February 27 at 21:25 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,preview","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614867842","isCrawlerRequest":true}